Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Jun 4 2010

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7^th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. The double blind placebo-controlled study consisted of a six-day, twice-daily intranasal administration of placebo or MRX-4 followed by an intranasal dose of allergen on the morning of the seventh day with a clinical follow-up and scoring over the next 24 hours. Blood, urine and pharmacokinetics (PK) analyses were also conducted.

The primary end-point of the study was safety with standard physiological and biochemical measurements taken and monitored. The secondary end-points of the study consisted of monitoring levels of inflammatory mediators (IL-5, IL-13, MCP-1, TNF-alpha, IL-8 and Eotoxin) as well as eosinophils in the nasal lavage and assessing MRX-4 clinical efficacy by monitoring clinical categories such as rhinorrhea, nasal itching, sneezing, frontal headache, nasal congestion and ear/palate itching.